UGT1A1 and neutropenia: UGT1A1 activity is the main factor determining cytotoxicity and AEs of irinotecan, and the US Food and Drug Administration has approved UGT1A1 genotyping to predict irinotecan-induced severe diarrhea and neutropenia [12].